Patrick Arbuthnot to Antiviral Agents
This is a "connection" page, showing publications Patrick Arbuthnot has written about Antiviral Agents.
Connection Strength
1,079
-
Countering hepatitis B virus infection using RNAi: how far are we from the clinic? Rev Med Virol. 2011 Nov; 21(6):383-96.
Score: 0,364
-
Hepatitis B virus: promising drug targets and therapeutic implications. Expert Opin Ther Targets. 2021 06; 25(6):451-466.
Score: 0,177
-
In vitro transcribed mRNA for expression of designer nucleases: Advantages as a novel therapeutic for the management of chronic HBV infection. Adv Drug Deliv Rev. 2021 01; 168:134-146.
Score: 0,166
-
Activating the innate immune response to counter chronic hepatitis B virus infection. Expert Opin Biol Ther. 2016 12; 16(12):1517-1527.
Score: 0,129
-
Differing prospects for the future of using gene therapy to treat infections with hepatitis B virus and hepatitis C virus. Discov Med. 2015 Sep; 20(109):137-43.
Score: 0,120
-
In Vivo Modelling of Hepatitis B Virus Subgenotype A1 Replication Using Adeno-Associated Viral Vectors. Viruses. 2021 11 09; 13(11).
Score: 0,046
-
Improved Specificity and Safety of Anti-Hepatitis B Virus TALENs Using Obligate Heterodimeric FokI Nuclease Domains. Viruses. 2021 07 12; 13(7).
Score: 0,045
-
Improved antiviral efficacy using TALEN-mediated homology directed recombination to introduce artificial primary miRNAs into DNA of hepatitis B virus. Biochem Biophys Res Commun. 2016 09 30; 478(4):1563-8.
Score: 0,032